🧠 Food for thought

Implications, context, and why it matters.

Innorna’s pipeline has not hit pre-IPO milestones

• The Phase II Respiratory Syncytial Virus (RSV) vaccine in China tests doses in healthy adults 60 or older 1. Phase III has not begun, and no program has reached pivotal trials that can lift valuations before an IPO.
• Herpes zoster (shingles) vaccine has Investigational New Drug (IND) clearance 2. IND status only permits human testing. No Phase I readout, partnerships, or Good Manufacturing Practice (GMP) capacity are disclosed, limiting visibility on time to revenue.
• Innorna cites a proprietary lipid nanoparticle (LNP) library of 6,000+ ionizable lipids (molecules engineered to carry charge to help RNA enter cells) 1. No sign that any formulation beats LNPs used by Moderna or BioNTech, so platform edge remains unproven.

Service firms can target Hong Kong’s biotech IPO pipeline

• Hong Kong had 48 active Chapter 18A and 18C applications in October 2025 3. On Sept 29–30, over 10 pharma and biotech firms filed A1s 4. IR, compliance, translation shops can pitch using Hong Kong Exchanges and Clearing’s (HKEX) A1 filing database (the exchange’s repository for initial listing applications).
• The May 2025 TECH channel, HKEX’s route for specialist tech, allows confidential filing 5. That shift opens earlier pre-IPO roadshow prep for institutional IR teams while companies guard sensitive data and build investor pipelines.
• Mainland issuers filed 34 biotech IPOs in H1 2025 5, while healthcare deals averaged 30.4% first-day gains 6. Virtual roadshow platforms and investor targeting tools have a short window to engage prospects before pricing.